Hemogenyx Pharmaceuticals innovates brain cancer treatment with CBR delivery
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group, has made a significant advancement in medical science by demonstrating the ability to deliver its proprietary ... Read More
Kazia Therapeutics gets fast track status for paxalisib in glioblastoma
Kazia Therapeutics, an Australian oncology company, has secured fast track designation (FTD) from the US Food and Drug Administration (FDA) for paxalisib (formerly GDC-0084) for ... Read More
Kazia Therapeutics gets US RPDD for paxalisib in childhood brain cancer
Kazia Therapeutics, an Australian biotech company, has secured the rare pediatric disease designation (RPDD) for paxalisib (formerly GDC-0084) from the US Food and Drug Administration ... Read More